NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 75 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare NeurAxis to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.
Insider and Institutional Ownership
11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 43.8% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for NeurAxis and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
NeurAxis Competitors | 240 | 738 | 1976 | 101 | 2.63 |
Earnings & Valuation
This table compares NeurAxis and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NeurAxis | $2.46 million | -$14.63 million | -0.63 |
NeurAxis Competitors | $1.00 billion | $86.74 million | 2.95 |
NeurAxis’ competitors have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares NeurAxis and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -594.55% | N/A | -899.27% |
NeurAxis Competitors | -156.39% | -48.87% | -5.51% |
Summary
NeurAxis competitors beat NeurAxis on 9 of the 12 factors compared.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.